List of Biologics Companies in Ohio - 30

3BarBio offers increased profitability to discovery companies, bulk suppliers, and distributors by addressing the major hurdle to further adoption of biologics by designing innovative packaging to deliver viable microbes to the ag market. With its proprietary LiveMicrobe® Design. Develop. Deliver. process, 3Bar delivers on demand for partners around the world.

Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development. Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.

Created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is in advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns.

Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University. EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. Based on the pioneering work by the scientific founders, Matthias Clauss, PhD and Irina Petrache, MD, and their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and their network of preclinical and clinical scientists, have demonstrated a pivotal pathogenic role of EMAP II in cardiopulmonary diseases, including pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.

Armatus Bio is a biotechnology company that specializes in precision gene therapy for raising expectations in FSHD.

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

BioHeights LLC specializes in business strategy for novel cell and gene therapies. We help companies, startups, and academic institutions.

Case Western Reserve University is a Higher Education institution that offers research and academic programs.

Celloram Inc. is a preclinical stage company founded in 2018. Our team of experienced leaders and scientists share a passion for improving the health and well-being of patients and families affected by cancer and chronic disease. Celloram has a deep sense of social responsibility. We are dedicated to the community in which we reside and work, and where we honor our commitment to promote diversity by inspiring, educating and developing the next generation of scientists and leaders. Celloram now leverages its key discoveries to develop unique forms of cell therapy and small molecule therapeutics that harness our body’s own unique potential to heal and battle chronic illnesses including cancer, autoimmune disease, chronic inflammatory and metabolic disorders. Our mission and vision stem from our strong belief in the potential of new, less toxic therapies with the power to ignite our body’s self-healing process. With an ideal location at University Circle, Cleveland, OH, Celloram has benefited greatly from partnerships with health care leaders at two of the nation’s leading academic medical centers, including Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. Supported by a highly motivated and dedicated group of partners and investors, Celloram has developed a pipeline of four unique therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022. These cutting-edge therapies are in distinct phases of preclinical development and are rapidly advancing through essential steps that will position each core asset for entry into clinical trials and evaluation by the FDA. Our team at Celloram is committed to sharing our discoveries and advancing them for the benefit of human health.

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal, and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

One of the few FDA-licensed cord blood centers in the U.S., the Cleveland Cord Blood Center (CCBC) collects, processes, stores and distributes stem-cell rich umbilical cord blood for transplantation in patients with life-threatening disorders.

Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell targeting to restore hepatocyte metabolism and treat metabolic diseases. Restoring hepatocyte function addresses the root dysregulations in common metabolic diseases like diabetes, obesity, and dyslipidemia. Our therapies leverage the Hepatocyte's natural regulatory functions, aiming to deliver superior patient outcomes and improved disease management.

Eikonoklastes Therapeutics is an early stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet clinical need, starting with neurodegenerative diseases. We are iconoclasts who are passionate about finding new and better ways to treat disease. Our first-in-class gene therapy moves beyond single defective gene replacement. It is a transformational, disease-modifying gene supplement therapy with a unique mechanism of action that provides extra copies of a critical gene to cause overexpression of a critical neurotrophic factor that is essential for neuromuscular signaling and function. Our initial focus is on Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease), a rare, yet debilitating nerve disease that causes progressive muscle degeneration and eventual death. An estimated 5,000 new patients in the U.S. are diagnosed each year with ALS, and there are few treatment options beyond supportive care. Our dynamic discovery and development approach allows us to focus on accelerated approvals and outsized returns for ALS and potentially other neurodegenerative diseases such as Parkinson’s, Huntington’s, Alzheimer’s, traumatic brain injury, and more.

We are a specialty CDMO for LV vector manufacture & use. Our three platforms: Expression Cassette Optimization (ECO), LentET (3rd gen system), & LentET Express (cGMP mfg.) enable GMP LV manufacture 10 months from sequence submittal. ECO increases expression up to 8 fold. LentET plasmids are ECO optimized, have improved safety, produce potent LVs & may be available royalty/licensing free depending upon the specifics. With full CMC & regulatory support, Expression is your preferred CDMO of choice.

Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.

Genosera is revolutionizing the gene therapy field with its next generation gene therapy treatments that can help stop the progression of diseases and allow patients to regain their health. Founded in 2019, Genosera is a privately held, gene therapy biotechnology company located in Columbus, Ohio.

Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.

Heidelberg University is a higher education institution offering a variety of academic programs and research opportunities.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian's products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers, and agri-bio companies in more than 70 countries around the world. Meridian's website address is www.meridianbioscience.com.

NovAccess Global is a biomedical company accelerating and investing in novel cancer diagnostics and therapeutics.

NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases.

Onconetix (formerly Blue Water Biotech Inc.) (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. The company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.

Optimvia is a biopharmaceutical company specializing in engineering enzymes and their cofactors to synthesize complex therapeutic molecules. The company leverages its ADEPT™ platform to engineer biosynthetic heparin and aims to manufacture non-animal derived heparin as proof of principle for its platform.

ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever. With AAGP, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve. ProtoKinetix has harnessed a molecule found in nature with the power to transform lives and the future of health care. Founded in 2002, ProtoKinetix secured a patent for anti-aging glycopeptide (AAGP), a naturally-occurring molecule that regenerates cells for animals surviving in arctic temperatures. AAGP has gone through a series of tests in laboratories throughout Europe and North America conducted by some of the best researchers in the world. Backed by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable and effective in protecting and regenerating cells. This molecule could be the link to improved treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease and so much more. There is endless potential, and we’ve only seen the tip of the iceberg. Become part of the next great medical discovery.

Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers.

We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the effective reversal of aging. We are looking for investors, development partners, or licensees. Interested parties please contact us for further information and discussions.

University Hospitals is a healthcare provider that offers medical services and patient care.